Description Module
The Description Module contains narrative descriptions of the clinical trial, including a brief summary and detailed description. These descriptions provide important information about the study's purpose, methodology, and key details in language accessible to both researchers and the general public.
Description Module path is as follows:
Study -> Protocol Section -> Description Module
Description Module
Ignite Creation Date:
2025-12-24 @ 10:53 PM
Ignite Modification Date:
2025-12-24 @ 10:53 PM
NCT ID:
NCT07164469
Brief Summary:
This clinical research study is to learn if CD70.CAR NK cell therapy can help to control early relapsed or primary refractory DLBCL and cHL.
Detailed Description:
Primary Objective:
The primary objective of the study is to determine the efficacy of CB-derived CD70.CAR NK cell therapy in patients with primary refractory or early relapsed DLBCL and HL, as determined by the 2-year event-free survival rate.
Secondary Objectives:
* To determine the antitumor activity pf CB-derived CD70.CAR NK cells, as determined by the response rate (ORR) and complete response (CR) rate.
* To establish the safety of this treatment.
* To quantify the persistence of infused CB-derived CD70.CAR NK cells in the peripheral blood.
* To conduct comprehensive immune studies by evaluating tissue and blood-based biomarkers associated with response and resistance to CD70.CAR NK cells.
Study:
NCT07164469
Study Brief:
Protocol Section:
NCT07164469